Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ The Destruction of Peloton Continues (24/7 Wall St.) +++ PELOTON Aktie +7,96%

CENCORA Aktie

 >CENCORA Aktienkurs 
292.2 EUR    -2.8%    (TradegateBSX)
Ask: 292.95 EUR / 110 Stück
Bid: 291.5 EUR / 110 Stück
Tagesumsatz: 11 Stück
Realtime Kurs von 7:30 bis 22 Uhr!
CENCORA Aktie über LYNX handeln
>CENCORA Performance
1 Woche: -1,8%
1 Monat: +0,4%
3 Monate: +4,0%
6 Monate: +24,8%
1 Jahr: +28,0%
laufendes Jahr: +5,0%
>CENCORA Aktie
Name:  CENCORA DL-,01
Land:  USA
Sektor:  Handel
ISIN/ Wkn:  US03073E1055 / 766149
Symbol/ Ticker:  ABG (Frankfurt) / COR (NYSE)
Kürzel:  FRA:ABG, ETR:ABG, ABG:GR, NYSE:COR
Index:  S&P500
Webseite:  https://www.cencora.com/
Profil:  Cencora Inc., formerly known as AmerisourceBergen Corporation, represents a pivotal entity in the global healthcare distribution and services sector. As a leading pharmaceutical sourcing and distribut..
>Volltext..
Marktkapitalisierung:  59628.45 Mio. EUR
Unternehmenswert:  65037.19 Mio. EUR
Umsatz:  285351.96 Mio. EUR
EBITDA:  4292.24 Mio. EUR
Nettogewinn:  1423.54 Mio. EUR
Gewinn je Aktie:  7.34 EUR
Schulden:  6938.73 Mio. EUR
Liquide Mittel:  1584.25 Mio. EUR
Operativer Cashflow:  3756.54 Mio. EUR
Bargeldquote:  0.03
Umsatzwachstum:  -5.29%
Gewinnwachstum:  2.6%
Dividende je Aktie:  0.72 EUR
Dividendenrendite:  0.66%
Dividendenschätzung:  0.69%
Div. Historie:  09.03.26 - 0.181797€
08.12.25 - 0.18028499€
>weitere anzeigen...
Insiderhandel:  1 Insider verkaufte innerhalb der letzten 30 Tage Aktien im Wert von 1.829.492 USD.
Suchwörter:  CENCORA, AMERISOURCEBERGEN
Letzte Datenerhebung:  17.03.26
>CENCORA Kennzahlen
Aktien/ Unternehmen:
Aktien: 194.53 Mio. St.
Frei handelbar: 99.6%
Rückkaufquote: 0.03%
Mitarbeiter: 51000
Umsatz/Mitarb.: 5.52 Mio. EUR
Analysten:
Analystenrating: Buy
Kursziel: 17.23%
Bewertung:
KGV: 42.96
KGV lG: 19.86
KUV: 0.21
KBV: 36.41
PEG-Ratio: 2.27
EV/EBITDA: 15.15
Rentabilität:
Bruttomarge: 3.28%
Gewinnmarge: 0.5%
Operative Marge: 1.18%
Managementeffizenz:
Gesamtkaprendite: 2.2%
Eigenkaprendite: 152.25%
>CENCORA Peer Group
Handel, Apotheken
 
17.03.26 - 14:18
Cencora CFO James Cleary Set To Retire (AFX)
 
WASHINGTON (dpa-AFX) - Cencora, Inc. (COR), a distributor of pharma products, Tuesday announced that its Chief financial Officer and Executive Vice President, James Cleary will retire on June 30.T......
17.03.26 - 13:42
Cencora CFO Cleary to retire in June 2026; reaffirms FY26 EPS outlook (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
17.03.26 - 13:33
Cencora Announces Financial Leadership Transition (Business Wire)
 
Cencora reaffirms fiscal 2026 financial guidanceCONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that James F. Cleary will retire as Executive Vice President and Chief Financial Officer effective June 30, 2026. Cencora has engaged an executive search firm to identify and evaluate potential successors from internal and external candidates. Mr. Cleary will assist in the search process and will serve in an advisory capacity through the end of 2026 to help ensure a smooth transition. Mr. Cleary, 62, has served as Cencora's CFO since November 2018. He joined the Company in February 2015, following its acquisition of MWI Veterinary Supply, where he had served as Chief Executive Officer for over a decade. “On behalf of the Board and Enterprise Leadership Team, I want to thank Jim for his years of pragmatic leadership, strategic insight and consistent financial stewardship,” said Robert P. Mauch, President and Chief Executive Officer of Cencora. “Jim retires with an outstanding...
10.03.26 - 22:01
Cencora auf der Leerink-Konferenz: Strategische Weichenstellungen und Wachstumspläne (Investing.com DE)
 
Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...
10.03.26 - 15:42
Cencora auf Barclays-Konferenz: Starkes US-Wachstum trotz Preisdruck (Investing.com DE)
 
Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...
06.03.26 - 14:00
Is Cencora Stock Outperforming the S&P 500? (Barchart)
 
Um den gesamten Artikel unter newsbreak.com zu lesen, klicken Sie bitte auf die Überschrift...
05.03.26 - 13:01
NexCure, Inc. Launches with $19 Million Series A Financing to enable CAR-T and other advanced treatment delivery in community outpatient settings (PR Newswire)
 
– NexCure founded by Raven, RA Capital's healthcare incubator, to address capacity constraints and access challenges for lifesaving therapies – – Financing led by RA Capital with participation from Cencora Ventures and Oncology Ventures – BOSTON, March 5, 2026 /PRNewswire/ -- NexCure, Inc.......
25.02.26 - 02:01
Insiderhandel: President & CEO verkauft Aktien von Cencora im Wert von 1350332 USD (Insiderkauf)
 
Mauch, Robert P. - Vorstand - Tag der Transaktion: 2026-02-20...
20.02.26 - 23:01
Insiderhandel: President & CEO verkauft Aktien von Cencora im Wert von 479160 USD (Insiderkauf)
 
Mauch, Robert P. - Vorstand - Tag der Transaktion: 2026-02-18...
19.02.26 - 15:01
COR′s MWI Animal Health to Merge With Covetrus in $3.5 Billion Deal (Zacks)
 
Cencora is set to merge MWI Animal Health with Covetrus in a $3.5B deal, retaining a 34.3% stake as it unlocks capital and targets animal health growth....
18.02.26 - 14:06
Cencora Announces Merger Deal Of Covetrus And MWI Animal Health To Empower Veterinary Practices (AFX)
 
WASHINGTON (dpa-AFX) - Cencora, Inc. (COR) Covetrus, a global animal health technology and services company, Wednesday announced an agreement to merge the latter with MWI Animal Health, creating a......
18.02.26 - 13:03
Covetrus and MWI Animal Health to Merge (Business Wire)
 
Combination of companion animal distribution, production animal distribution and technology platforms will make animal healthcare more accessible and affordable Transaction unites complementary businesses to deliver innovative, efficient solutions and expertise across the entire animal health ecosystem Deal values MWI at an enterprise value of $3.5 billion. Cencora to receive cash proceeds of $1.25 billion and $800 million of preferred equity while retaining a non-controlling common equity stake of 34.3% in the combined company Cencora reaffirms fiscal 2026 financial guidance CONSHOHOCKEN, Pa. & PORTLAND, Maine--(BUSINESS WIRE)--Cencora (NYSE: COR) and Covetrus, a global animal health technology and services company, today announced that they have entered into a definitive agreement under which Covetrus and MWI Animal Health (MWI) will merge, creating a combined company offering a comprehensive animal health platform. “Our mission has always been to empower veterinary practices to work smarter and deliv...
13.02.26 - 22:21
Cencora Closes $3.0 Billion Senior Notes Offering (Business Wire)
 
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced the closing of its public offering of $500 million aggregate principal amount of its 3.950% Senior Notes due February 13, 2029 (the “2029 Notes”), $500 million aggregate principal amount of its 4.250% Senior Notes due November 15, 2030 (the “2030 Notes”), $500 million aggregate principal amount of its 4.600% Senior Notes due February 13, 2033 (the “2033 Notes”), $1.0 billion aggregate principal amount of its 4.900% Senior Notes due February 13, 2036 (the “2036 Notes”) and $500 million aggregate principal amount of its 5.650% Senior Notes due February 13, 2056 (the “2056 Notes” and, together with the 2029 Notes, the 2030 Notes, the 2033 Notes and the 2036 Notes, the “Notes”), in an underwritten registered public offering. The offering was made pursuant to an effective shelf registration statement Cencora filed with the Securities and Exchange Commission (the “SEC”) on November 26, 2024. Cencora intends...
10.02.26 - 23:31
Cencora prices $3B in senior notes across multiple maturities (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
10.02.26 - 23:18
Cencora Prices $500 Million 3.950% Senior Notes Due 2029, $500 Million 4.250% Senior Notes Due 2030, $500 Million 4.600% Senior Notes Due 2033, $1.0 Billion 4.900% Senior Notes Due 2036 and $500 Million 5.650% Senior Notes Due 2056 (Business Wire)
 
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that it priced $500 million aggregate principal amount of its 3.950% Senior Notes due February 13, 2029 (the “2029 Notes”), $500 million aggregate principal amount of its 4.250% Senior Notes due November 15, 2030 (the “2030 Notes”), $500 million aggregate principal amount of its 4.600% Senior Notes due February 13, 2033 (the “2033 Notes”), $1.0 billion aggregate principal amount of its 4.900% Senior Notes due February 13, 2036 (the “2036 Notes”) and $500 million aggregate principal amount of its 5.650% Senior Notes due February 13, 2056 (the “2056 Notes” and, together with the 2029 Notes, the 2030 Notes, the 2033 Notes and the 2036 Notes, the “Notes”), in an underwritten registered public offering. The offering is being made pursuant to an effective shelf registration statement Cencora filed with the Securities and Exchange Commission (the “SEC”) on November 26, 2024. The offering is expected to close...
10.02.26 - 14:06
What Are Wall Street Analysts' Target Price for Cencora Stock? (Barchart)
 
Um den gesamten Artikel unter newsbreak.com zu lesen, klicken Sie bitte auf die Überschrift...
09.02.26 - 16:42
Chief Executives for Corporate Purpose: Chief Executives for Corporate Purpose Announces Covista Chairman and CEO Steve Beard, Cencora Inc. Former Executive Chair Steven H. Collis, and Ann Fairchild, interim President and CEO of Siemens USA Joining B (Accesswire)
 
NEW YORK CITY, NY / ACCESS Newswire / February 9, 2026 / Chief Executives for Corporate Purpose (CECP) announced today that three distinguished executives will join the organization's Board of Dire......
04.02.26 - 19:45
Cencora Stock Down Despite Q1 Earnings Beat, Gross Margin Improves (Zacks)
 
COR shares slip despite Q1 EPS beat and revenues match estimates, margins expand and fiscal 2026 growth guidance up....
04.02.26 - 19:15
Cencora outlines 11.5%-13.5% operating income growth for 2026 while integrating OneOncology (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
04.02.26 - 18:00
Cencora Lifts 2026 Sales Outlook Despite Q1 Revenue Miss (Benzinga)
 
Cencora reported higher Q1 earnings but missed revenue estimates, driven by U.S. and European drug sales growth. Importance Rank:  1 read more...
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Illusionen sind eine Sache, die ein Mann gleichzeitig mit seinen Haaren und Zähnen verliert. - Franziska Friedl
>Aktien | >Anleihen | >ETFs | >Fonds | >Branchen | >Länder | >Themen | >Redaktionen
Partner:    >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!